South Africa Genomic Diagnostics Market Report 2023 to 2030

South Africa Genomic Diagnostics Market Analysis

$ 3999

South Africa Genomic Diagnostics Market was valued at $212.23 Mn in 2023 and is predicted to grow at a CAGR of 17.73% from 2023 to 2030, to $665.28 Mn by 2030. The key drivers of this industry include increasing prevalence, technological advancements, and demand for personalized medicine. The industry is primarily dominated by Illumina, 23andMe, Myriad Genetics, and Amgen among others.

ID: IN10ZAHS054 CATEGORY: Healthcare Services GEOGRAPHY: South Africa AUTHOR: Sarita Yadav

Buy Now

South Africa Genomic Diagnostics Market Executive Summary

South Africa Genomic Diagnostics Market was valued at $212.23 Mn in 2023 and is predicted to grow at a CAGR of 17.73% from 2023 to 2030, to $665.28 Mn by 2030.

Genomic diagnostics is a rapidly evolving field that uses an individual's genetic information to diagnose diseases, assess predisposition to future health problems, and guide treatment plans by analyzing DNA or RNA for disease-linked variations. This includes karyotyping to examine chromosome abnormalities, targeted mutation analysis for specific disease-related genes, and next-generation sequencing (NGS) for a comprehensive genetic analysis. Applications encompass disease diagnosis, carrier testing for informed family planning, predictive testing for disease risk assessment, and pharmacogenomics for personalized medication treatments. The benefits of genomic diagnostics include early disease detection, personalized medicine, and improved disease management and prognosis.

In 2022, South Africa had a senior population of 5.9%, which is below the 7% threshold that defines an aging population. In 2019, the country faced significant health challenges, with 4.7 Mn people suffering from hypertension or high blood pressure, 1.7 Mn from HIV and AIDS, 1.6 Mn from diabetes, and 1.2 Mn from arthritis. These statistics highlight the prevalence of chronic health conditions among South Africans.

Market is therefore driven by significant factors like increasing prevalence, technological advancements, and demand for personalized medicine. However, high costs, shortage of skilled professionals, and limited access in rural areas restrict the growth and potential of the market.

A prominent player in this field is Illumina, which has partnered with AstraZeneca to leverage genomics and AI for faster drug development by identifying new therapeutic targets and biomarkers, 23andMe acquired Lemonaid Health to enhance its personalized healthcare offerings through telehealth and prescription drug delivery services based on genetic information. Other contributors include Myriad Genetics, and Amgen among others.

South Africa Genomic Diagnostics Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Increasing Prevalence: The rise in chronic diseases, in 2019, the country faced significant health challenges, with 4.7 Mn people suffering from hypertension or high blood pressure, 1.7 Mn from HIV and AIDS, 1.6 Mn from diabetes, and 1.2 Mn from arthritis, is boosting the demand for genomic diagnostics in South Africa, where healthcare challenges are significant.

Technological Advancements: Innovations such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) are improving diagnostic accuracy and efficiency, making genomic tests more accessible to healthcare providers and patients.

Demand for Personalized Medicine: The growing recognition of personalized medicine's importance is driving demand for genomic diagnostics, as patients and healthcare providers seek tailored treatment options based on genetic information.

Market Restraints

High Costs: The high cost of genomic diagnostics is a major barrier to widespread adoption, particularly in lower-income areas where healthcare systems struggle to afford advanced testing technologies.

Shortage of Skilled Professionals: A lack of trained personnel in genomic diagnostics limits the effective use and interpretation of these tests, posing a challenge to market expansion.

Limited Access in Rural Areas: In rural regions, underdeveloped healthcare infrastructure restricts access to advanced diagnostic services, limiting the overall market potential.Bottom of Form

Regulatory Landscape and Reimbursement Scenario

In South Africa, the regulation of medical devices and in vitro diagnostics, including genomic tests, falls under the purview of the South African Health Products Regulatory Authority (SAHPRA). SAHPRA ensures the safety, quality, and efficacy of health products, playing a critical role in the approval of new genomic tests.

Reimbursement for genomic diagnostics in South Africa is complex and influenced by various factors. The country is working towards implementing a National Health Insurance (NHI) system, which could impact genomic test reimbursement in the future. Currently, private medical aid schemes provide varying levels of coverage, and many individuals rely on out-of-pocket payments. Key challenges include limited coverage focused on high-impact conditions, the need to demonstrate cost-effectiveness for favorable reimbursement, and disparities in access based on socioeconomic status and geographical location.

Competitive Landscape

Key Players

Here are some of the major key players in the South Africa Genomic Diagnostics

Illumina, Inc.
Myriad Genetics, Inc.
Amgen, Inc.
23andMe
Agilent Technologies
Perkin Elmer
Thermo Fisher Scientific
QIAGEN
Nihon Kohden Corporation
Siemens Healthineers

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

South Africa Genomic Diagnostics Market Segmentation

By Technology

Next Generation Sequencing
Array Technology
PCR-based Testing
FISH
Others

By Application

Ancestry & Ethnicity
Traits Screening
Genetic Disease Carrier Status
New Baby Screening
Health and Wellness-Predisposition/Risk/Tendency

By Product

Consumables
Equipment
Software & Services

By End-user

Hospitals & Clinics
Diagnostic Laboratories
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.